BioSpace News Archive

Aatru Medical, LLC (“Aatru”) announced today that its technical Abstract has been accepted for presentation at both the SAWC/WHS 2020 conference in North Carolina and also at EWMA 2020, to be held in London, England.

Ivenix, Inc., a medical technology company with the vision of eliminating infusion-related patient harm, today announced its successful development and testing with Epic, furthering Ivenix’s commitment of smart pump interoperability

The Department of Health and Human Services (HHS) OCIO, Office of Executive Service (OES) awarded Aveshka a three-year, $6.3 million contract to help HHS meet and improve compliance with Section 508 requirements. Section 508 mandates federal agencies to ensure information and communications technology is accessible to both government

510(k) Clearance allows 23andMe to report interpretive drug information for medications prescribed for heart conditions and depression without the need for confirmatory testing

Calviri, Inc. announces today the appointment of Michael Chambers to the Calviri Board of Directors.

Tolmar Pharmaceuticals, Inc., a specialty pharmaceutical company, today affirmed the full availability of FENSOLVI® (leuprolide acetate) for injectable suspension in its six-month dose (45mg) for pediatric patients with central precocious puberty (CPP)

Biocom, the association representing the California life science industry, today announced the endorsement of California Proposition 14, the Stem Cell Research Institute Bond Initiative.

Bintai Kinden Corporation Berhad ( www.bintai.com.my ) is an investment holding company headquartered in Malaysia with operations throughout South-East Asia, China, and the Arabian Gulf Region Upfront development payment 100% funding for commercial registration of Ii-Key- SARS-CoV-2 prophylactic vaccine against COVID-19 in Malaysia Licensing fees upon approval Potential $150 million in GNBT revenues for vaccine sales in Malaysia MIRAMAR, Fla., Aug. 18, 2020 (GLOBE NEWSWIRE) -- This pr

Milliman, Inc. today announced the acquisition of Torch Insight® from Leavitt Partners, LLC.

Significant advancement achieved with ARDS-003 sterile injectable nano-emulsion finished drug product